Carbohydrate antigen 125 (CA125) is a 5797 bp transmembrane glycoprotein that is expressed by the fetal amniotic membrane, the luminal epithelium, and in the luminal epithelium (mesothelial cells of the pleura, pericardium and peritoneum) and the Müllerian duct It is expressed in adult tissues (fallopian tube, endometrium, and endocervix), and the concentration of CA125 is significantly increased when these sites undergo malignant transformation or are stimulated by inflammatory conditions. The level of CA125 in patients with epithelial ovarian cancer will be significantly increased, but at the same time CA125 will also indicate other malignant tumors, such as endometrial cancer, fallopian tube cancer, cervical cancer, breast cancer, lymphoma, mesothelial cell cancer, lung cancer, gastric cancer, liver cancer, etc. The study found that expression of the CA125 cytoplasmic tail enables tumor cells to grow and promotes cell motility and possibly invasion. In addition, CA125 plays a role in reducing the sensitivity of cancer cells to drug treatment. Therefore, targeting CA125 has great potential in the field of tumor diagnosis and treatment. CD ComputaBio provides CA125 targeting services to customers to accelerate the progress of their research.

Our Services

• Targeted Protein Structural Analysis

The structure of the binding site of CA125 molecule was obtained by X-ray single crystal diffraction technique or 3D structure simulation of the existing homologous molecule;

• Analysis of Target Protein Properties

Use molecular simulation software to analyze the structural properties of the CA125 binding site, such as electrostatic field, hydrophobic field, hydrogen bonding site distribution and other information;

• Lead Candidate Search

Use database search or new drug molecule design technology to identify molecules whose molecular shape and physicochemical properties match the CA125 action site;

• Candidate Compound Validation

Synthesize and test the biological activity of these molecules, and after several cycles, new lead compounds can be discovered.

Our Advantage

• Use DRID, GREEN, HSITE and other active site analysis software, combined with software based on Monte Carlo and simulated annealing technology to quickly and accurately find atoms or groups that interact well with the active site of biological macromolecules;
• Flexible selection of ligand-based (commonly used software such as Catalyst and Unity, etc.) and receptor-based (commonly used software such as DOCK, F1exX and GOLD, etc.) search methods for database search;
• For cases where suitable lead compounds cannot be found in the compound database, we can design new compounds through software such as LUDI, Leapfrog, GROW, SPROU and LigBuilder.

Our Capabilities

In each therapeutic area, CD ComputaBio has accumulated deep expertise in discovery informatics, computational chemistry/molecular modeling, medicinal chemistry, structural biology, in vivo and in vitro pharmacology, and translational science. During the drug discovery process, our team focuses on early lead compounds in different target classes and uses a wide range of techniques, including molecular screening, molecular modeling, medicinal chemistry, structural biology, bioinformatics and computational chemistry, to identify new target the direction of drug development, and then select suitable drug candidates through low-cost, high-efficiency computer simulations to ensure high efficiency and low risk in the later drug development process. Our computational biology team has extensive experience in the research of CA125 targets. Please consult our professional team for details.